{"denoms":[{"counts":[{"groupId":"BG000","value":"267"},{"groupId":"BG001","value":"262"},{"groupId":"BG002","value":"529"}],"units":"Participants"}],"groups":[{"description":"Participants received sacituzumab govitecan 10 mg/kg of body weight, administered as a slow IV infusion either by gravity or with an infusion pump on Days 1 and 8 of a 21-day treatment cycle for up to 29.6 months. Infusion rate for the first 15 minutes started with 50 mg/hour or less with a subsequent infusion of 100 to 200 mg/hour up to a maximum recommended rate (advanced every 15 to 30 minutes) of 500 mg/hour with a subsequent infusion of 1000 mg/hour. Participants continued treatment until progression of disease requiring treatment discontinuation or occurrence of unacceptable AEs.","id":"BG000","title":"Sacituzumab Govitecan"},{"description":"Participants received TPC (ie, eribulin, capecitabine, gemcitabine, or vinorelbine), administered as a single-agent regimen that was selected by the investigator before participant randomization. Participants continued treatment until progression of disease requiring treatment discontinuation or occurrence of unacceptable AEs.\n\nEribulin was administered IV over 2 to 5 minutes at a dose 1.4 mg/m\\^2 at North American sites and 1.23 mg/m\\^2 at European sites on Days 1 and 8 of a 21-day cycle for up to 15.3 months. Lower doses were administered on the same schedule to participants with moderate hepatic impairment (ie, Child-Pugh B; 0.7 mg/m\\^2 and 0.67 mg/m\\^2 for North American and European sites, respectively).\n\nCapecitabine 1000 to 1250 mg/m\\^2 was administered in a 21-day cycle, with capecitabine administered orally twice daily for 2 weeks followed by 1-week rest period for up to 10.6 months.\n\nGemcitabine 800 to 1200 mg/m\\^2 was administered IV over 30 minutes on Days 1, 8, and 15 of a 28-day cycle for up to 8.1 months.\n\nVinorelbine 25 mg/m\\^2 was administered as a weekly IV injection over 6-10 minutes for up to 11.5 months. Vinorelbine was not allowed as TPC for any participant with Grade 2 neuropathy.","id":"BG001","title":"Treatment of Physician's Choice (TPC)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.34","value":"54.0"},{"groupId":"BG001","spread":"11.69","value":"54.0"},{"groupId":"BG002","spread":"11.50","value":"54.0"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"265"},{"groupId":"BG001","value":"262"},{"groupId":"BG002","value":"527"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"45"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"234"},{"groupId":"BG001","value":"226"},{"groupId":"BG002","value":"460"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"24"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"22"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"62"}],"title":"Black"},{"measurements":[{"groupId":"BG000","value":"215"},{"groupId":"BG001","value":"203"},{"groupId":"BG002","value":"418"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"27"}],"title":"Other"}],"title":"Race"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"45"}]}],"title":"Belgium"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"}]}],"title":"Canada"},{"categories":[{"measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"62"}]}],"title":"France"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}]}],"title":"Germany"},{"categories":[{"measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"58"}]}],"title":"Spain"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"15"}]}],"title":"United Kingdom"},{"categories":[{"measurements":[{"groupId":"BG000","value":"172"},{"groupId":"BG001","value":"170"},{"groupId":"BG002","value":"342"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}],"populationDescription":"The Intent-to-Treat (ITT) Population included all randomized participants."}